Seagen

14 Decision Makers Β· 19 Verified Contacts & Email Format

πŸ“ Bothell, Washington, United StatesBiotechnologyπŸ—“ Est. 1998πŸ‘₯ 1001–5000 employees

About Seagen

Seagen is a clinical-stage biotechnology company dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.

Email Format

{first_letter_first_name}{last_name}@seagen.com β€” 37.5%

ssmith@seagen.com

{first_name}@seagen.com β€” 31.3%

sarah@seagen.com

{first_name}.{last_name}@seagen.com β€” 25.0%

sarah.smith@seagen.com

{first_letter_first_name}.{first_letter_middle_name}.{last_name}@seagen.com β€” 6.3%

s.j.smith@seagen.com

Leadership & Decision Makers

Contact details of 14 Seagen decision makers

Guy Padbury

Senior Vice President, Translational Sciences LinkedIn
  • Work email

    g******y@seagen.com

Bryce Mansfield

Executive Director, R&D Quality LinkedIn
  • Work email

    b********d@seagen.com

Kamran Ansari

VP, Head of Clinical Development Operations LinkedIn
  • Work email

    k*****i@seagen.com

Scott Orchard

Senior Vice President and Associate General Counsel, Head of Transactional Law
  • Work email

    s***********d@seagen.com

    Verified

Swapnil Bhargava

Director, BioProcess Development
  • Work email

    s*****l@seagen.com

    Verified

Wendel Doubleday

Sr. Director, Chemical Development
  • Work email

    w********y@seagen.com

    Verified

Mark Cooley

Executive Director, IT Strategy and Operations
  • Work email

    m**k@seagen.com

    Verified

Monique M. Greer

Vice President, Corporate Communications
  • Work email

    m*******r@seagen.com

    Verified

Michael Gerstle

Director
  • Work email

    m*****l@seagen.com

    Verified

Clay Siegall

Founder
  • Work email

    c**********l@seagen.com

    Verified

Qi Jiang

Senior Vice President, Head of Biometrics
  • Work email

    qi@seagen.com

    Verified

Peggy Pinkston

Senior Vice President, Investor Relations
  • Work email

    p************n@seagen.com

    Verified

Stephan Thebault

Senior Vice President, Global Head of Quality
  • Work email

    s**************t@seagen.com

    Verified

Cindy McDonald-Everett

Senior Vice President, Global Value Access

Team & Specialists

Contact details of 5 Seagen team members

Davina Sparks Henderson

Sr Manager. Field Reimbursement LinkedIn
  • Work email

    d********n@seagen.com

Virginie Oble Bouvet

LinkedIn
  • Work email

    v***e@seagen.com

Peter Senter

VP, Chemistry,VP, Distinguished Research Fellow
  • Work email

    p***r@seagen.com

Marcel Koopman

International Product Manager Oncology
  • Work email

    m******n@seagen.com

Jayeshkumar Soneji

  • Work email

    j*****i@seagen.com

General Emails

General company emails, e.g. customer support lines

    contact@seagen.com

    General Inquiries

    pcarter@seagen.com

    Unclassified inbox

    serviceclients@seagen.com

    Unclassified inbox

    ktreutlein@seagen.com

    Unclassified inbox

    pwalters@seagen.com

    Unclassified inbox

Similar Companies like Seagen

Fulgent Therapeutics

fulgentgenetics.com
Biotechnology Β· Temple City, California, United States Β· Est. 2011 Β· 1001–5000 employees

HQ: Temple City, California, United States

Horizon Pharma

horizontherapeutics.com
Pharmaceuticals Β· Northbrook, Illinois, United States Β· Est. 2005 Β· 1001–5000 employees

HQ: Northbrook, Illinois, United States

Moderna

modernatx.com
Biotechnology Β· Cambridge, MA Β· Est. 2010 Β· 1001–5000 employees

HQ: Cambridge, MA

Biotechnology Β· Boston, MA Β· Est. 1989 Β· 1001–5000 employees Β· $500M–$1B

HQ: Boston, MA

Biotechnology Β· Cheshire, Connecticut, United States Β· Est. 1992 Β· 1001–5000 employees

HQ: Cheshire, Connecticut, United States

Explore similar firms in the Biotechnology sector

Company Info

Last updated: 01/08/2025

6192707227

Bothell, Washington, United States

Specialization: Therapeutics,
Legal Name: Seattle Genetics, Inc.
Business Type: Public
Employees: 1001-5000
Rounds: Post-IPO Equity
Founded Date: 1998
Number of Exits: 2
Company Type: For Profit
Stock Symbol: NASDAQ:SGEN
Operating Status: Active
Last Funding Type: Post-IPO Equity
Phone Number: 6192707227
Last Investment Activity: Mar 12, 2024
Investments Activity: Mar 12, 2024 Mar 6, 2024 Mar 1, 2024

Our service is undergoing beta testing, and you can get all the information that is closed on this page for free by registering. You will not need to provide your credit/debit card details.